Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Natera’s genomic jargon isn’t easy. Each 10-K details everything from cfDNA assay accuracy to payer reimbursement disputes, while 8-K updates often cover fast-moving clinical-trial milestones. If you’ve ever wondered how to locate test-volume data, or needed Natera insider trading Form 4 transactions before the market reacts, you know the challenge.
Stock Titan solves it. Our AI reads every Natera quarterly earnings report 10-Q filing, highlights revenue per test, and translates accounting footnotes into plain language. Real-time alerts flag Natera Form 4 insider transactions real-time, so you can track executive stock moves the moment they hit EDGAR. Need the full picture? We link each 10-K, 10-Q, 8-K, proxy DEF 14A, and S-8 in one place—Natera SEC filings explained simply. Common questions such as “How do I find the latest Natera proxy statement executive compensation?” or “Where is the Natera 8-K material events explained?” are answered inside every filing card.
Our platform doesn’t stop at document delivery. AI-powered summaries spotlight what matters for a diagnostics company: R&D spend versus cash on hand, progress of the Signatera oncology pipeline, and changes in CMS reimbursement that can swing margins. Use cases include:
- Compare quarter-over-quarter test volumes without sifting through tables
- Monitor Natera executive stock transactions Form 4 for buying or selling trends
- Assess dilution risk by reviewing shelf registrations and ATM offerings
- Download an Natera annual report 10-K simplified PDF automatically annotated by AI
- Receive instant alerts when a new Natera earnings report filing analysis is available
- Get guidance on understanding Natera SEC documents with AI-generated glossaries
Whether you’re a healthcare analyst, portfolio manager, or clinician-investor, Stock Titan turns Natera’s dense disclosures into actionable insight—no genetics PhD required.
In this Form 4, Natera director and co-founder Sheena Jonathan reported sales totaling 6,070 shares of Natera common stock: 3,070 shares on 08/08/2025 and 3,000 shares on 08/11/2025. The filing lists weighted-average prices for the 08/08 sales roughly in the mid-$156 to mid-$164 range and for the 08/11 sales roughly in the low-$150 to mid-$156 range. Footnotes state the 08/08 sales were executed under a Rule 10b5-1 plan adopted December 11, 2024, and the 08/11 sales were executed under a separate Rule 10b5-1 plan adopted June 7, 2024.
Following these transactions the reporting person retained 242,252 shares reported as directly owned and reported indirect trust holdings associated with Caraluna trusts in the ~34,282–35,662 share range across the trust entries. No derivative securities were reported.
Insider Form 4 filing — Natera, Inc. (NTRA)
On 08/01/2025, Solomon Moshkevich (President, Clinical Diagnostics; officer) reported three sales of Natera common stock effected pursuant to a Rule 10b5-1 trading plan adopted on 11/26/2024. The reported dispositions were 1,574 shares at a weighted-average price of $132.4528 (range $131.9350–$132.78), 1,326 shares at $133.3097 (range $132.96–$133.80), and 100 shares at $134.08.
Post-transaction beneficial ownership: reported as 124,485; 123,159; and 123,059 shares respectively. The Form was signed by an attorney-in-fact on 08/05/2025.
Natera, Inc. (NTRA) filed a Form 144 indicating that insider Gail Marcus intends to sell up to 2,496 common shares through Merrill Lynch on or after 1 Aug 2025. The proposed sale is valued at $332,394.72, based on the market price at the time of filing. Natera has 136.55 million shares outstanding, so the planned sale equals <0.01 % of the float.
The shares were acquired via equity-compensation grants on 9 Jun 2024 (2,374 sh) and 26 Jul 2024 (122 sh). Marcus has already sold 12,299 shares over the past three months, generating gross proceeds of ≈$1.98 million (4,000 sh on 1 May 2025, 4,000 sh on 10 Jun 2025, 4,299 sh on 1 Jul 2025).
While the filing signals continued insider selling, the absolute volume remains immaterial relative to total shares and does not, by itself, imply a change in the company’s fundamentals.
FAQ
What is the current stock price of Natera (NTRA)?
What is the market cap of Natera (NTRA)?
